Glucocorticoid-Associated Demise of a Patient with Duchenne Muscular Dystrophy

Alexander E. Brahmsteadt, John R. Bach, Reza Pishdad, Lissette Cespedes, Paola Pierucci

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


We describe the clinical deterioration of a 26-yr-old man with Duchenne muscular dystrophy on oral daily high-dose deflazacort. Although this daily regimen was targeted to benefit ambulation and respiration, it resulted in premature death with lethal sequelae from liver failure, decubiti, diabetes mellitus, and morbid obesity. This case illustrates the need for further research weighing risk versus benefit of daily glucocorticoid therapy, specifically deflazacort, in Duchenne muscular dystrophy patients. Thus, curtailment of daily dosing to eliminate dire sequelae in patients living longer into adulthood than ever before is recommended.

Original languageEnglish (US)
Pages (from-to)e146-e148
JournalAmerican Journal of Physical Medicine and Rehabilitation
Issue number12
StatePublished - Dec 2020

All Science Journal Classification (ASJC) codes

  • Physical Therapy, Sports Therapy and Rehabilitation
  • Rehabilitation


  • Deflazacort
  • Duchenne Muscular Dystrophy
  • Glucocorticoid
  • Neuromuscular Disease


Dive into the research topics of 'Glucocorticoid-Associated Demise of a Patient with Duchenne Muscular Dystrophy'. Together they form a unique fingerprint.

Cite this